U.S. markets open in 7 hours 30 minutes
  • S&P Futures

    4,210.00
    -13.00 (-0.31%)
     
  • Dow Futures

    33,906.00
    -111.00 (-0.33%)
     
  • Nasdaq Futures

    13,921.50
    -59.75 (-0.43%)
     
  • Russell 2000 Futures

    2,302.00
    -8.10 (-0.35%)
     
  • Crude Oil

    71.94
    -0.21 (-0.29%)
     
  • Gold

    1,820.10
    -41.30 (-2.22%)
     
  • Silver

    27.14
    -0.68 (-2.43%)
     
  • EUR/USD

    1.2008
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5690
    0.0000 (0.00%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.4008
    +0.0021 (+0.15%)
     
  • USD/JPY

    110.6400
    +0.0270 (+0.02%)
     
  • BTC-USD

    38,752.95
    -1,539.69 (-3.82%)
     
  • CMC Crypto 200

    963.75
    -28.72 (-2.89%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,036.33
    -254.68 (-0.87%)
     

Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP).

  • Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the European Medicines Agency (EMA).

  • Fast track is a process designed to facilitate the development and expedite the review of drugs.

  • BP is a severe orphan autoimmune inflammatory blistering skin disease wherein both terminal complement activation (via complement component C5), and the lipid mediator leukotriene B4 (LTB4) have a central role in driving the disease.

  • Akari's lead drug candidate, Nomacopan, is a C5 complement inhibitor that independently and specifically binds to and inhibits leukotriene B4 (LTB4) activity.

  • Price Action: AKTX shares are up 2.13% at $2.39 during the market trading session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.